Podcast (The Weekly Bioanalysis) Eps #98: “Special Guest: Scott Weir, University of Kansas Medical Center”

In the newest episode of “The Weekly Bioanalysis” podcast, our hosts, John and Dom welcome Scott Weir (Director, Institute for Advancing Medical Innovation at KU Medical Center) for a practical, behind-the-scenes look at how drug discovery and development can be executed in an academic setting—and what it takes to translate promising lab or bedside discoveries into real clinical programs. Scott breaks down the process through three clear “pillars” that guide early development: does the drug reach the site of action, engage the target, and produce the intended pharmacologic response—from preclinical studies through early-phase trials. He also explains how KU builds a “virtual biotech” model by combining industry-experienced teams, university core infrastructure, and CRO partners like KCAS Bio, including a discussion of their “triple threat” CAR-T program (CD19/20/22) manufactured on-site in a GMP cellular therapy facility. The conversation goes deeper into the realities of cost, bioanalytical and biomarker needs across modalities, and how public–private partnerships help academic programs cross the “valley of death” from animal proof-of-concept to clinical proof-of-concept.

To view/listen to the episode of “the Weekly Bioanalysis” click the play button below!